Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA
Inzucchi S, Tan X, Liang Y, Yedigarova L, Xie L, de Havenon A. Cardiovascular Events in Adults with Type 2 Diabetes and ASCVD Initiating Once-Weekly Semaglutide vs DPP-4is in the USA. Diabetes Therapy 2024, 1-17. PMID: 39688779, DOI: 10.1007/s13300-024-01678-4.Peer-Reviewed Original ResearchHealth care resource utilizationAtherosclerotic cardiovascular diseaseDPP-4i usersDPP-4isGLP-1 RAsOnce-weekly semaglutideMedical costsType 2 diabetesDPP-4iDecreased risk of strokeRisk of cardiovascular outcomesCardiovascular eventsOnce-weekly GLP-1 RAsPeptide 1 receptor agonistsTotal medical costsDipeptidyl peptidase 4 inhibitorsOccurrence of cardiovascular eventsHigh-risk patientsRisk of strokeObservational cohort analysisData Mart DatabaseOutpatient visitsDecreased riskSemaglutide treatmentBaseline characteristics